EuroBloodNet is endorsing three Preceptorships programs to provide applicants with the fundamental tools for a correct diagnostic and treatment approach to bone marrow failures, including AA and PNH in children, adolescents and adult patients.
The meeting has provided the perfect opportunity for patients to experience what Patient and Public Involvement is while demonstrated the that the medical profession is willing to change and listen to the patient voice.
An open-label, phase 1 gene therapy study consisting of autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with a lentiviral vector encoding for the PK enzyme is now enrolling patients
All abstracts of presentations will be published in the upcoming Hemoglobin Journal, including “EuroBloodNet: A European Reference Network for Rare Blood Diseases and a Model for Emulation”
RELEVANCE results provides the basis for the new Marie Curie - ITN EVIDENCE (Erythrocytes properties and viability in dependence of flow and extra-cellular environment) which is already recruiting students
ERN-EuroBloodNet ERN-EuroBloodNet Hôpital St Louis / Université Paris 7 1 avenue Claude Vellefaux 75475 PARIS, France
ERN-EuroBloodNet is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are supported by the European Commission. For more information about the ERNs and the EU health strategy, please visit http://ec.europa.eu/health/ern
You are receiving this newsletter because you are part of the EuroBloodNet inventory of members or because you subscribed. Your data is gathered and processed in line with the General Data Protection Regulation and in accordance with EuroBloodNet Policy. You can unsubscribe any time by clicking below or contacting coordination@eurobloodnet.eu.
